Tositumomab has been approved in the United States and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


tositumomab studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
CP-98-020 IV Expanded access study of Iodine-131 anti-B1 antibody for relapsed/refractory low-grade and transformed low-grade non-Hodgkin’s lymphoma
CP-98-025 III Fludarabine monophosphate followed by Iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin’s lymphoma
RIT-II-004 III Multicenter, pivotal Phase 3 study of Iodine-131 Tositumomab (murine) radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
393229/032 II A single arm, open label, multicentre, phase II study of Tositumomab and Iodine I 131-Tositumomab in subjects with indolent non-Hodgkin’s Lymphoma who have previously received rituximab.
CP-97-011 II Phase II study of Iodine-131 anti-B1 antibody for 1st or 2nd relapsed indolent B-cell lymphomas or B-cell lymphomas that have transformed to a more aggressive histology.
CP-97-012 II Phase II study of iodine I 131 Tositumomab for non-Hodgkin’s lymphoma patients who have previously received Rituximab
CP-98-021 II Retreatment study of patients with non-Hodgkin’s lymphoma who have previously responded to iodine I 131 Tositumomab
CP-99-036 II Phase II multicenter study of CVP followed by Iodine-131 anti-B1 antibody for patients with untreated low-grade non-Hodgkin’s lymphoma.
RIT-I-000 II Phase I/II study of radiolabeled monoclonal antibody anti-B1 for the treatment of B-cell lymphomas.
RIT-II-001 II Multicenter, phase II dosimetry/validation study of 131 Iodine anti-B1 (murine) radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies
RIT-II-002 II A randomized study of Iodine-131 Anti-B1 Antibody versus Anti-B1 Antibody in chemotherapy-relapsed/refractory low-grade or transformed low-grade non-Hodgkin’s Lymphoma (NHL).
RIT-II-003 II Phase II trial of Iodine-131 Anti-B1 Antibody for previously untreated, advanced-stage, low-grade non-Hodgkin’s lymphoma
CP-98-018 I A phase I, dose-escalation, open label, multicenter study of Iodine-131 anti-B1 antibody for intermediate- and high-risk B-cell chronic lymphocytic leukemia
CP-98-028 I Phase 1, dose-escalation study of Iodine-131 anti-B1 antibody for patients with previously treated non-Hodgkin’s lymphoma with more than 25% bone marrow involvement